Key Takeaways
- • IGIS Asia Investment Management and CHA Bio Group have formed a joint venture to establish an Asia-Pacific life science real estate investment platform targeting R&D, manufacturing, and healthcare facilities across the region.
- • The partnership leverages IGIS's track record in real estate transactions combined with CHA's expertise in biopharma and life sciences to capture first-mover advantage in life science real estate solutions in South Korea and overseas markets.
- • IGIS plans to establish the Korea Life Science Investment Platform (KLSIP), the first Korea-focused investment vehicle dedicated to life science real estate, designed to support the growing domestic biotech and pharmaceutical sector.
- • The venture will develop and invest in high-quality life science assets including R&D facilities, manufacturing plants, hospitals, medical offices, and healthcare centers across Asia-Pacific metropolitan areas.
- • IGIS is South Korea's largest real estate investment manager, while CHA Bio Group is one of the country's oldest and largest biopharma groups with significant global operations, positioning the JV to serve companies ranging from biotech incubators to multinational pharmaceutical corporations.
Summary
IGIS Asia Investment Management, the pan-Asian investment arm of IGIS Asset Management (South Korea's largest real estate investment manager), has announced a strategic partnership with CHA Bio Group, one of South Korea's oldest and largest biopharma enterprises with extensive global reach, to establish a new Asia-Pacific life science real estate investment platform. The joint venture represents a coordinated effort to address the rapidly expanding demand for specialized real estate infrastructure supporting the life sciences sector across the region.
The venture targets institutional-quality life science facilities spanning multiple asset classes: R&D laboratories, manufacturing plants, hospitals, medical offices, and supporting healthcare centers. The platform is designed to serve a broad spectrum of end-users, from early-stage biotech incubators to multinational pharmaceutical corporations operating across Asia-Pacific. The two partners view the platform as a catalyst for accelerating life science sector growth in the region, particularly as demand patterns shift and new market challenges emerge requiring specialized real estate solutions.
IGIS and CHA are strategically positioned to dominate this emerging niche through complementary capabilities. IGIS brings an established track record in large-scale real estate transactions and asset management expertise, while CHA contributes deep domain knowledge of the life sciences industry, regulatory frameworks, and operator requirements across biopharma and healthcare sectors. This combination is intended to provide first-mover advantage in developing life science real estate solutions, particularly in South Korea and other Asia-Pacific markets where such specialized infrastructure remains underdeveloped.
As a cornerstone of the venture, IGIS plans to establish the Korea Life Science Investment Platform (KLSIP), described as the first Korea-focused investment vehicle dedicated exclusively to life science real estate. KLSIP is designed to secure dedicated capital to develop facilities that address the specific demands of South Korea's growing life science industry, signaling both companies' confidence in the sector's expansion trajectory and their intent to build a scalable, capital-backed platform.
The venture targets institutional-quality life science facilities spanning multiple asset classes: R&D laboratories, manufacturing plants, hospitals, medical offices, and supporting healthcare centers. The platform is designed to serve a broad spectrum of end-users, from early-stage biotech incubators to multinational pharmaceutical corporations operating across Asia-Pacific. The two partners view the platform as a catalyst for accelerating life science sector growth in the region, particularly as demand patterns shift and new market challenges emerge requiring specialized real estate solutions.
IGIS and CHA are strategically positioned to dominate this emerging niche through complementary capabilities. IGIS brings an established track record in large-scale real estate transactions and asset management expertise, while CHA contributes deep domain knowledge of the life sciences industry, regulatory frameworks, and operator requirements across biopharma and healthcare sectors. This combination is intended to provide first-mover advantage in developing life science real estate solutions, particularly in South Korea and other Asia-Pacific markets where such specialized infrastructure remains underdeveloped.
As a cornerstone of the venture, IGIS plans to establish the Korea Life Science Investment Platform (KLSIP), described as the first Korea-focused investment vehicle dedicated exclusively to life science real estate. KLSIP is designed to secure dedicated capital to develop facilities that address the specific demands of South Korea's growing life science industry, signaling both companies' confidence in the sector's expansion trajectory and their intent to build a scalable, capital-backed platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.